» Articles » PMID: 37533246

Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where Do We Go from Here?

Overview
Date 2023 Aug 3
PMID 37533246
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinsonian disorders are a heterogeneous group of incurable neurodegenerative diseases that significantly reduce quality of life and constitute a substantial economic burden. Nuclear imaging (NI) and magnetic resonance imaging (MRI) have played and continue to play a key role in research aimed at understanding and monitoring these disorders. MRI is cheaper, more accessible, nonirradiating, and better at measuring biological structures and hemodynamics than NI. NI, on the other hand, can track molecular processes, which may be crucial for the development of efficient diseasemodifying therapies. Given the strengths and weaknesses of NI and MRI, how can they best be applied to Parkinsonism research going forward? This review aims to examine the effectiveness of NI and MRI in three areas of Parkinsonism research (differential diagnosis, prodromal disease identification, and disease monitoring) to highlight where they can be most impactful. Based on the available literature, MRI can assist with differential diagnosis, prodromal disease identification, and disease monitoring as well as NI. However, more work is needed, to confirm the value of MRI for monitoring prodromal disease and predicting phenoconversion. Although NI can complement or be a substitute for MRI in all the areas covered in this review, we believe that its most meaningful impact will emerge once reliable Parkinsonian proteinopathy tracers become available. Future work in tracer development and high-field imaging will continue to influence the landscape for NI and MRI.

References
1.
Lehericy S, Vaillancourt D, Seppi K, Monchi O, Rektorova I, Antonini A . The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. Mov Disord. 2017; 32(4):510-525. DOI: 10.1002/mds.26968. View

2.
Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

3.
Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L . The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies. Sleep Med Rev. 2018; 43:37-46. DOI: 10.1016/j.smrv.2018.09.008. View

4.
Boeve B, Silber M, Ferman T, Lin S, Benarroch E, Schmeichel A . Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013; 14(8):754-62. PMC: 3745815. DOI: 10.1016/j.sleep.2012.10.015. View

5.
Varrone A, Pagani M, Salvatore E, Salmaso D, Sansone V, Amboni M . Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2007; 34(7):1071-81. DOI: 10.1007/s00259-006-0344-7. View